sdbn.org

News, Syndication, Xconomy »

Amylin, Alkermes Win FDA Approval of Once-Weekly Diabetes Drug
Posted by sandiegobiotech January 27th, 2012 .
No Comments

[Updated: 3:47 pm] Amylin Pharmaceuticals and Alkermes have gone to the FDA twice before to seek approval of their new diabetes drug, and been turned back, but now the persistence has paid off. The...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

2012 Venture Outlook: Some Bright Spots and Some Gloom
Posted by sandiegobiotech January 27th, 2012 .
No Comments

It’s that outlook time of year, and Mark Heesen, president of the National Venture Capital Association (NVCA), was in San Diego earlier this week, talking about the 2012 outlook for venture capital....

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Why Biogen Idec Got Out of the Corporate VC Business
Posted by sandiegobiotech January 27th, 2012 .
No Comments

Steve Holtzman got his first taste of corporate venture capital back in 1987, when he raised money from SR One, back when it was part of an old company known as Smith, Kline & French. The concept...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Illumina, Sequenom, Acutus, & More
Posted by sandiegobiotech January 26th, 2012 .
No Comments

The unsolicited $5.7 billion offer that Roche made for Illumina will no doubt dominate San Diego’s biotech news for weeks to come. We have it and more. —Switzerland’s Roche offered $5.7 billion, or...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Roche Makes $5.7B Hostile Takeover Bid for Illumina
Posted by sandiegobiotech January 25th, 2012 .
No Comments

San Diego-based Illumina, the market leading maker of DNA sequencing instruments, has just made it through a rough year, and now it may be entering its final chapters as an independent company....

[[Click headline to continue reading.]] More...

Drug Development, News, Syndication, Xconomy »

Angry at the Genome
Posted by sandiegobiotech January 24th, 2012 .
No Comments

In 2004, I was an enthusiastic postdoctoral researcher in Eric Lander’s lab at the Broad Institute, with the job I had dreamed of since I was 10 years old. Growing up in Paducah, KY, I read Isaac...

[[Click headline to continue reading.]] More...

Drug Development, News, Syndication, Xconomy »

Angry at the Genome
Posted by sandiegobiotech January 24th, 2012 .
No Comments

In 2004, I was an enthusiastic postdoctoral researcher in Eric Lander’s lab at the Broad Institute, with the job I had dreamed of since I was 10 years old. Growing up in Paducah, KY, I read Isaac...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Vertex Vows to Fight On With Alios Drugs in High-Stakes Hepatitis C Race
Posted by sandiegobiotech January 24th, 2012 .
No Comments

Vertex Pharmaceuticals went from king of the hill in the treatment of hepatitis C to yesterday’s news in about six wild months. But while many on Wall Street say Vertex’s big drug will soon become...

[[Click headline to continue reading.]] More...

News, Syndication, Xconomy »

Biotech Is Raising More Cash, But Don’t Be Fooled: Startups are Hurting
Posted by sandiegobiotech January 23rd, 2012 .
No Comments

Mark Twain used to toss around a saying about three kinds of lies. There are lies, damned lies, and statistics. This week in biotech, we saw some statistics that could lead some people to get a false...

[[Click headline to continue reading.]] More...

Drug Development, News, Syndication, Xconomy »

In Life Sciences Partnerships, You Must be Smart from the Beginning
Posted by sandiegobiotech January 20th, 2012 .
No Comments

As early stage biotech startups advance their drug candidates into pre-clinical development, many must decide at some point whether to start working with a big pharmaceutical or biotech partner to...

[[Click headline to continue reading.]] More...